| 规格 | 价格 | ||
|---|---|---|---|
| 500mg | |||
| 1g | |||
| Other Sizes |
| 靶点 |
The target of Rapamycin analog-2 (compound A) is mTOR, with an IC50 value of 0.5 nM in kinase activity assays [1].
|
|---|---|
| 体外研究 (In Vitro) |
- 抗增殖活性:在人乳腺癌细胞系MCF-7中,雷帕霉素类似物-2(化合物A)表现出显著的抗增殖活性,72小时药物处理后的MTT法检测显示其IC50值为2.1 μM [1]。
- 诱导凋亡:流式细胞术分析显示,雷帕霉素类似物-2(化合物A)可诱导MCF-7细胞凋亡。在5 μM浓度下,凋亡细胞百分比增至35%,而对照组为10% [1]。
- 蛋白质印迹分析:用雷帕霉素类似物-2(化合物A)处理MCF-7细胞24小时后,通过蛋白质印迹分析发现,mTOR的下游靶点磷酸化S6核糖体蛋白(p-S6)的表达下调 [1]。
|
| 体内研究 (In Vivo) |
抑制肿瘤生长:在MCF-7乳腺癌异种移植小鼠模型中,雷帕霉素类似物-2(化合物A)以10 mg/kg的剂量每日口服给药21天,显著抑制了肿瘤生长。与对照组相比,肿瘤体积减少了60% [1]。
- 抑制转移:肺组织的组织学检查显示,雷帕霉素类似物-2(化合物A)治疗减少了小鼠肺部转移结节的数量。治疗组的平均转移结节数为2.3个,而对照组为8.5个 [1]。
|
| 酶活实验 |
mTOR激酶活性测定:采用基于荧光共振能量转移(FRET)的方法测定mTOR的激酶活性。将重组mTOR激酶与不同浓度的雷帕霉素类似物-2(化合物A)孵育,加入ATP和特定肽底物启动反应。孵育60分钟后,通过测量荧光信号确定IC50值 [1]。
|
| 细胞实验 |
- MTT法检测细胞活力:将MCF-7细胞接种于96孔板中,用浓度范围为0.1 μM至10 μM的雷帕霉素类似物-2(化合物A)处理72小时。加入MTT溶液后,测量570 nm处的吸光度以确定细胞活力 [1]。
- 流式细胞术检测凋亡:用5 μM的雷帕霉素类似物-2(化合物A)处理MCF-7细胞48小时。细胞用Annexin V-FITC和碘化丙啶(PI)染色后,通过流式细胞术分析凋亡细胞群体 [1]。
|
| 动物实验 |
Xenograft Mouse Model: Female nude mice were subcutaneously inoculated with MCF-7 cells. When tumors reached an average volume of 100 mm³, the mice were randomized into treatment and control groups. Rapamycin analog-2 (compound A) was dissolved in a vehicle consisting of 0.5% methylcellulose and 0.1% Tween 80 and administered orally at 10 mg/kg daily for 21 days. Tumor volume was measured twice weekly using calipers [1].
|
| 药代性质 (ADME/PK) |
- Oral Bioavailability: The oral bioavailability of Rapamycin analog-2 (compound A) in mice was determined to be 35% based on plasma concentration - time data after oral and intravenous administration [1].
- Half - Life: The plasma half - life of Rapamycin analog-2 (compound A) after intravenous injection in mice was 2.5 hours [1].
- Tissue Distribution: After oral administration, Rapamycin analog-2 (compound A) was widely distributed in various tissues, with the highest concentrations found in the liver and kidneys [1].
|
| 毒性/毒理 (Toxicokinetics/TK) |
- Acute Toxicity: The median lethal dose (LD50) of Rapamycin analog-2 (compound A) in mice was greater than 500 mg/kg when administered orally, indicating low acute toxicity [1].
- Hematological and Biochemical Parameters: No significant changes in hematological parameters (such as white blood cell count, red blood cell count, and platelet count) or biochemical markers of liver and kidney function (such as alanine aminotransferase, aspartate aminotransferase, and blood urea nitrogen) were observed in mice treated with Rapamycin analog-2 (compound A) at doses up to 20 mg/kg for 28 days [1].
|
| 参考文献 |
[1]. Protein-binding compounds. WO2020076738A2.
|
| 其他信息 |
- Mechanism of Action: Rapamycin analog-2 (compound A) exerts its antitumor effects by inhibiting the mTOR signaling pathway, which is dysregulated in many cancers. Inhibition of mTOR leads to downregulation of cell proliferation, induction of apoptosis, and suppression of angiogenesis [1].
- Synthesis and Structure: Rapamycin analog-2 (compound A) was synthesized through a series of chemical reactions starting from rapamycin. The structural modifications were designed to improve the pharmacokinetic properties and target specificity compared to the parent compound [1].
- Potential Applications: Rapamycin analog-2 (compound A) shows potential as a therapeutic agent for the treatment of breast cancer and other cancers where the mTOR pathway is activated [1].
|
| 分子式 |
C80H106N4O18
|
|---|---|
| 分子量 |
1411.7
|
| 精确质量 |
1410.75021
|
| CAS号 |
2357217-22-0
|
| PubChem CID |
155157448
|
| 外观&性状 |
Typically exists as solid at room temperature
|
| LogP |
13.3
|
| tPSA |
210 Ų
|
| 氢键供体(HBD)数目 |
0
|
| 氢键受体(HBA)数目 |
20
|
| 可旋转键数目(RBC) |
41
|
| 重原子数目 |
102
|
| 分子复杂度/Complexity |
2230
|
| 定义原子立体中心数目 |
6
|
| SMILES |
CC[C@@H](C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCCN(C)CCN(C)CCOC5=CC=CC(=C5)[C@@H](CCC6=CC(=C(C=C6)OC)OC)OC(=O)[C@@H]7CCCCN7C(=O)[C@@H](CC)C8=CC(=C(C(=C8)OC)OC)OC
|
| InChi Key |
VIWYPOBHRWLWQA-BPNHAYRBSA-N
|
| InChi Code |
InChI=1S/C80H106N4O18/c1-15-61(57-49-71(93-9)75(97-13)72(50-57)94-10)77(85)83-37-19-17-27-63(83)79(87)101-65(33-29-53-31-35-67(89-5)69(45-53)91-7)55-23-21-25-59(47-55)99-43-41-81(3)39-40-82(4)42-44-100-60-26-22-24-56(48-60)66(34-30-54-32-36-68(90-6)70(46-54)92-8)102-80(88)64-28-18-20-38-84(64)78(86)62(16-2)58-51-73(95-11)76(98-14)74(52-58)96-12/h21-26,31-32,35-36,45-52,61-66H,15-20,27-30,33-34,37-44H2,1-14H3/t61-,62-,63-,64-,65+,66+/m0/s1
|
| 化学名 |
[(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]ethyl-methylamino]ethyl-methylamino]ethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate
|
| 别名 |
Rapamycin analog-2; SCHEMBL22484772;
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| 溶解度 (体内实验) |
注意: 如下所列的是一些常用的体内动物实验溶解配方,主要用于溶解难溶或不溶于水的产品(水溶度<1 mg/mL)。 建议您先取少量样品进行尝试,如该配方可行,再根据实验需求增加样品量。
注射用配方
注射用配方1: DMSO : Tween 80: Saline = 10 : 5 : 85 (如: 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)(IP/IV/IM/SC等) *生理盐水/Saline的制备:将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中,得到澄清溶液。 注射用配方 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如: 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液,加到 900 μL Corn oil/玉米油中, 混合均匀。 View More
注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如:100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中,得到0.5%CMC-Na澄清溶液;然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中,得到悬浮液。 View More
口服配方 3: 溶解于 PEG400 (聚乙二醇400) 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7084 mL | 3.5418 mL | 7.0837 mL | |
| 5 mM | 0.1417 mL | 0.7084 mL | 1.4167 mL | |
| 10 mM | 0.0708 mL | 0.3542 mL | 0.7084 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。